ROCKVILLE, Md.--(BUSINESS WIRE)--Bacilligen, Inc., an early-stage Biotechnology Company in Rockville, announced today that the Company has accepted a $50,000 investment from the State’s Challenge Investment Program fund. The program, part of the Maryland Department of Business and Economic Development’s (DBED) Maryland Venture Fund, is designed to assist small start-up companies in the high technology sector. The funding will strengthen Bacilligen’s ability to advance its three technology platforms and more quickly bring to market treatments and vaccines for the oncology and infectious disease markets, as well as advance a novel rapid biologics manufacturing system.
